However, following the description and characterization of IL-17 and Th17 cells, more and more data indicated that these latter types of CD4+ cells are key players in the development of RA and that anti-IL-17 therapies might have beneficial effects [3]. This evidence concerns the gene CD4 and rheumatoid arthritis.